Of the NSCLC specimens in this exploratory cohort, 8/8 (100%) expressed VEGFR2 in the vasculature, and 2/8 (25.0%) in tumor cells – both of which were SCC. This evidence concerns the gene KDR and non-small cell lung carcinoma.